Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab alone versus daratumumab plus abatacept for resistant active antibody-mediated rejection after kidney transplantation
2026-526730-73-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in humoral rejection comparing Daratumumab alone with Daratumumab plus abatacept (2 arms). Planned start Sep 2026; status: authorised.
02
Drugs
daratumumababatacept
03
Conditions
humoral rejection
Beyond the preview
Go deeper on 2026-526730-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526730-73-00.